HIGH END CELLOMICS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Market Challenges And Opportunities

High End Cellomics Market Drivers:

• Technological Advancements in Cellomics Techniques: Significant technological advancements are being made in cellomics techniques, which is driving the growth of the high end cellomics market. Companies are developing advanced high-resolution microscopes, enhanced workflow cytometry systems, and innovative imaging software that allow more in-depth study of cell morphology, functionality, and behavior. For instance, expansion microscopy is an emerging technique that enables imaging subcellular structures at resolutions better than 60 nm. Similarly, multiplex immunofluorescence, imaging mass cytometry, and other cytomics methods are being used for high-parameter single cell analysis. These advanced technologies provide researchers tools to gain valuable insights not possible previously. For instance, in May 2023, Deepcell, a company that specializes in single-cell research powered by Artificial Intelligence (AI), announced its launch of the REM-I Platform, a high-dimensional platform for cell morphology analysis and sorting that includes the Axon data suite, Human Foundation Model, and benchtop equipment REM-I. The REM-I Platform, which combines single cell imaging, sorting, and high-dimensional analysis, will spur the creation of novel approaches to discovery in a variety of disciplines including developmental biology, cancer biology, and stem cell biology.
• Application in Drug Discovery and Personalized Medicine: The application of high end cellomics in drug discovery and development is contributing to market growth. Pharmaceutical companies are increasingly adopting high content screening and high-throughput cellomics for lead compound identification and toxicity testing. Moreover, cellomics aids in the development of personalized therapies by identifying specific biomarkers and drug targets based on an individual’s molecular profile. Companies are also utilizing patient-derived organoids, spheroids, and other in-vitro models in cellomics early in preclinical studies to make drug discovery more focused, rapid, and effective.
• Rising Incidence of Chronic and Infectious Diseases: The rising prevalence of chronic and infectious diseases like cancer, autoimmune disorders, and COVID-19 is driving the cellomics market growth. As per the World Health Organization (WHO), in 2020, 10 million people died of cancer accounting for nearly one in six deaths worldwide. Cellomics facilitates the understanding of disease pathogenesis at cellular and molecular level, which helps identify new diagnostic biomarkers and therapeutic targets. Moreover, cellomics is being applied to develop stem cell therapies, immunotherapies, and other advanced treatments for cancer and degenerative diseases.
• Investments in Life Science Research: Increased R&D spending and investments in life sciences globally has positively impacted the global high end cellomics market. According to estimates by the UNESO Institute for Statistics, global R&D reached a record high of almost US$ 1.7 trillion. Government and private funding in fundamental cell biology and translational medical research has grown. Many major initiatives like the Human Cell Atlas Project and NIH’s BRAIN initiative are underway. This provides resources for cellomics research and raises its adoption in clinical and biomedical applications.

High End Cellomics Market Opportunities:

• Emerging Markets: Developing countries present significant opportunities for the growth of the high end cellomics market. Countries like China, India, Brazil, and others are expected to witness the increased adoption of cellomics technologies driven by improving R&D infrastructure, investments in biomedicine, and government policy support. For instance, China has seen the rapid development of preclinical drug discovery programs integrated with high content imaging and high-throughput screens. Companies are also expanding their distribution networks in these high potential markets. For instance, Asia contributed for 57 percent of global GDP growth between 2015 and 2021, according to McKinsey & Company, a worldwide management consulting firm. Asia provided 42 percent of global GDP (at purchasing power parity) in 2021, more than any other region.4. It solidified its position as a significant player in global commerce. Asia contributed approximately 53% of global goods trade in 2021 and 59% of trade growth between 2001 and 2021.
• Process Automation and Artificial Intelligence (AI): Automation and AI are opening new prospects in cellomics. Advanced robotic liquid handling platforms and machine learning algorithms are enabling automated high throughput sample preparation, staining, image acquisition, and analysis. Companies like Recursion Pharmaceuticals and Healx are using AI for phenotypic screening. Cloud-based solutions improve data management and accessibility. Implementation of lab automation will increase productivity, improve standardization, and support the growth of the cellomics field. For instance, in July 2023, Recursion, a clinical stage TechBio company, announced a US$ 50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE). With this investment, the company plans to accelerate development of its AI foundation models for biology and chemistry, which in collaboration with NVIDIA, it intends to optimize and distribute to biotechnology companies using the NVIDIA cloud service.
• Point-of-Care Testing: Point-of-care cellomics testing presents opportunities for market expansion. Portable and easy to use cellomics tools that can be utilized in clinical settings are being developed. For example, cell morphology analyzers for cancer screening, miniaturized imaging cytometry for CD4 counting in HIV. Point-of-care cellomics can make precision diagnostics more accessible and support treatment monitoring and companion diagnostics. Players are focused on developing integrated microfluidic solutions for POC testing.
• Growing Use of Organ-on-a-Chip Models: The increasing use of organ-on-a-chip models in cellomics research provides growth opportunities. These are microfluidic cell culture devices with living cells arranged to mimic organ physiology in vitro. Companies like Emulate, TissUse, and CN Bio are offering organ chips for lung, kidney, intestine, brain, etc. These advanced organoid models enable studying complex cell interactions, disease pathways, and toxicity. Cellomics technologies like high content imaging provide detailed functional analysis of organ chips for preclinical drug testing.